Acute and chronic experimental Trypanosoma cruzi infection in the rat. Response to systemic treatment with recombinant rat interferon-gamma.
We examined the effects of recombinant rat interferon-gamma (IFN-gamma) injections on the parasitologic, serologic, immunologic and histopathologic features of acute and chronic experimental Trypanosoma cruzi (T. cruzi) infections in "l" rats. Upon infection at weaning, two rat groups were allocated to receive a 20-day cycle of IFN-gamma injections, 20,000 IU/rat each, which started at 1, and 7 days post-infection (pi). Treatment with IFN-gamma, initiated at either 1 or 7 days pi, resulted in comparatively lower peak parasitemias (P < 0.02) but in similar levels of anti-T. cruzi circulating antibodies and serum IFN-gamma activities. The latter appeared significantly increased during acute infection whereas biologically active tumor necrosis factor was virtually undetectable in serum from infected rats regardless of whether they had been given IFN-gamma or not. The prevalence of chronic focal myocarditis in IFN-gamma-treated infected rats showed no differences with respect to the one recorded in control-infected counterparts. The inverse CD4/CD8 ratio of spleen and lymph node T cells that usually accompanies chronic infection was reversed by IFN-gamma. Mononuclear cells carrying class II I-A and I-E molecules, that were found to have increased at both compartments, appeared also modified upon IFN-gamma treatment with an overincrease of I-A-positive cells, and a normalization of I-E-bearing cells.
Revelli
S
S
Instituto de Inmunología, Facultad de Ciencias Médicas Universidad Nacional de Rosario, Argentina.
Davila
H
H
Ferro
M E
ME
Romero-Piffiguer
M
M
Musso
O
O
Valenti
J
J
Bernabo
J
J
Falcoff
E
E
Wietzerbin
J
J
Bottasso
O
O
D000208:Acute Disease; D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis; D016516:CD4-CD8 Ratio; D014355:Chagas Disease / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002908:Chronic Disease; D004195:Disease Models, Animal; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007371:Interferon-gamma / Q000032:analysis / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000166:cytology; D008297:Male; D009205:Myocarditis / Q000209:etiology / Q000473:pathology; D018512:Parasitemia / Q000276:immunology / Q000473:pathology / Q000628:therapy; D015995:Prevalence; D051381:Rats; D011994:Recombinant Proteins; D013154:Spleen / Q000166:cytology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014349:Trypanosoma cruzi / Q000187:drug effects* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000913:Antibodies, Protozoan; D000949:Histocompatibility Antigens Class II; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma